Skip to Main Content

Camostat mesylate in COVID-19 Outpatients

Conditions

Diseases of the Respiratory Systems | COVID-19 Outpatient

Phase COVID-IIa

What is the purpose of this trial?

The rationale of the present clinical trial is that an orally available drug given to outpatients that could reduce the viral burden in the upper respiratory tract could forestall complications of SARS-CoV-2 infection and reduce transmission from one infected individual to another.

  • Trial with
    Ono Pharmaceutical Co., Ltd.
  • Start Date
    06/16/2020
  • End Date
    05/30/2021
Trial Image

For more information about this study, contact:

Jeanine May

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/11/2020
  • Study HIC
    #2000027971